Kornelia Polyak

Q: What Schools Are Affiliated With Kornelia Polyak

Kornelia Polyak is affiliated with the following schools: Case Western Reserve University, Johns Hopkins University, Duke University, University of Cambridge, Seoul National University, Harvard University, University of Oslo, Weizmann Institute of Science, University College London, Vanderbilt University

Kornelia Polyak's AcademicInfluence.com Rankings

Kornelia Polyak

Law

#1779

World Rank

#2221

Historical Rank

Common Law

#49

World Rank

#54

Historical Rank

law Degrees

Kornelia Polyak

Philosophy

#4030

World Rank

#6400

Historical Rank

Logic

#1579

World Rank

#2371

Historical Rank

philosophy Degrees

Download Badge

Law
Philosophy

Kornelia Polyak's Degrees

Doctorate Medicine Harvard University

Why Is Kornelia Polyak Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert. Polyak earned her MD from Albert Szent-Gyorgyi Medical University in Szeged, Hungary, and her PhD from Weill Cornell Graduate School of Medical Sciences/Sloan-Kettering Cancer Center in New York City. She then did a fellowship in cancer genetics at Johns Hopkins Oncology Center with Bert Vogelstein and Kenneth Kinzler.

(See a Problem?)

Kornelia Polyak's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells (2008) (8195)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits (2009) (3183)
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis (2007) (3008)
The Genomic Landscapes of Human Breast and Colorectal Cancers (2007) (2549)
A model for p53-induced apoptosis (1997) (2531)
Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals (1994) (2268)
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. (1998) (2005)
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. (1994) (1928)
Intra-tumour heterogeneity: a looking glass for cancer? (2012) (1681)
A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice (1996) (1610)
Molecular definition of breast tumor heterogeneity. (2007) (1415)
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex (1995) (1411)
Tumor heterogeneity: causes and consequences. (2010) (1365)
Molecular characterization of the tumor microenvironment in breast cancer. (2004) (1287)
14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression (1997) (1160)
Sequence analysis of mutations and translocations across breast cancer subtypes (2012) (1133)
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state (2011) (1095)
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. (1995) (1060)
lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin (1994) (1006)
Somatic mutations of the mitochondrial genome in human colorectal tumours (1998) (841)
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. (2011) (820)
Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 Kip1 ) of cyclin-dependent kinase 4 activation (1994) (792)
Analysis of human transcriptomes (1999) (783)
Heterogeneity in breast cancer. (2011) (772)
Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene (2007) (613)
Co-evolution of tumor cells and their microenvironment. (2009) (597)
Breast cancer: origins and evolution. (2007) (592)
14-3-3sigma is a p53-regulated inhibitor of G2/M progression. (1997) (579)
Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. (1993) (565)
Toward understanding and exploiting tumor heterogeneity (2015) (557)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. (2019) (538)
Regulation of in situ to invasive breast carcinoma transition. (2008) (521)
Contribution of bone marrow–derived endothelial cells to human tumor vasculature (2005) (519)
Distinct epigenetic changes in the stromal cells of breast cancers (2005) (505)
Genetic determinants of p53-induced apoptosis and growth arrest. (1996) (502)
Tumorigenesis: it takes a village (2015) (457)
A public database for gene expression in human cancers. (1999) (447)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (439)
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer (2015) (437)
Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? (2007) (429)
Cellular heterogeneity and molecular evolution in cancer. (2013) (428)
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. (2013) (419)
Ductal carcinoma in situ of the breast. (2004) (398)
Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer (2010) (388)
Roots and stems: stem cells in cancer (2006) (386)
Oncogene-like induction of cellular invasion from centrosome amplification (2014) (358)
The microenvironment in breast cancer progression: biology and implications for treatment (2011) (357)
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. (1995) (349)
An anatomy of normal and malignant gene expression (2002) (326)
Microenvironmental regulation of cancer development. (2008) (325)
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. (2010) (324)
The role of the microenvironment in mammary gland development and cancer. (2010) (310)
Molecular markers in ductal carcinoma in situ of the breast. (2003) (290)
Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity (2014) (282)
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. (2020) (281)
Classifying the evolutionary and ecological features of neoplasms (2017) (276)
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas (2008) (273)
DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma (2003) (269)
A SAGE (serial analysis of gene expression) view of breast tumor progression. (2001) (250)
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. (2014) (243)
The cancer stem cell hypothesis: in search of definitions, markers, and relevance (2008) (239)
Cell type-specific DNA methylation patterns in the human breast (2008) (235)
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020) (234)
The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival (2017) (230)
Moving AHEAD with an international human epigenome project (2008) (202)
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ (2009) (202)
Role of COX-2 in epithelial–stromal cell interactions and progression of ductal carcinoma in situ of the breast (2009) (199)
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. (2006) (197)
Do Myoepithelial Cells Hold the Key for Breast Tumor Progression? (2005) (188)
The Origins and Implications of Intratumor Heterogeneity (2010) (185)
RNA sequencing of cancer reveals novel splicing alterations (2013) (179)
Genetic and phenotypic diversity in breast tumor metastases. (2014) (175)
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome (2014) (169)
Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. (1996) (166)
JARID1B is a luminal lineage-driving oncogene in breast cancer. (2014) (150)
Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung (2004) (150)
MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. (2014) (149)
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. (2017) (145)
Gene discovery using the serial analysis of gene expression technique: implications for cancer research. (2001) (144)
HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells (2001) (143)
In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2+ breast cancer (2015) (138)
p 27 Kip 1 , a cyclin-Cdk inhibitor , links transforming growth factor-13 and contact inhibition to cell cycle arrest (2007) (138)
PIK3CA mutations in in situ and invasive breast carcinomas. (2010) (137)
Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. (1996) (136)
Intratumoral Heterogeneity: More Than Just Mutations. (2019) (135)
Molecular characterisation of the tumour microenvironment in breast cancer. (2008) (134)
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. (2018) (133)
PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling (2011) (133)
Mammalian antiproliferative signals and their targets. (1995) (132)
BRCA1 haploinsufficiency for replication stress suppression in primary cells (2014) (132)
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. (2009) (125)
Targeting Akt3 signaling in triple-negative breast cancer. (2014) (125)
A neural survival factor is a candidate oncogene in breast cancer (2003) (123)
CDX2 is mutated in a colorectal cancer with normal APC/β-catenin signaling (1999) (123)
Cancer stem cells: a model in the making. (2009) (123)
Evolutionary pathways in BRCA1-associated breast tumors. (2012) (120)
Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression) (2002) (120)
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. (2013) (115)
Intratumor Heterogeneity in Breast Cancer. (2016) (115)
Identifying tumor origin using a gene expression-based classification map. (2003) (109)
Genome-wide functional synergy between amplified and mutated genes in human breast cancer. (2008) (108)
Psoriasin expression in mammary epithelial cells in vitro and in vivo. (2002) (106)
Origin of carcinoma associated fibroblasts (2009) (103)
Estrogen Receptor/Progesterone Receptor-Negative Breast Cancers of Young African-American Women Have a Higher Frequency of Methylation of Multiple Genes than Those of Caucasian Women1 (2004) (99)
Cellular and molecular targets of estrogen in normal human breast tissue. (2002) (98)
Epithelial and Stromal Cathepsin K and CXCL14 Expression in Breast Tumor Progression (2008) (98)
Precancer Atlas to Drive Precision Prevention Trials. (2017) (98)
Cancer chromosomes in crisis (2004) (97)
Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. (2000) (96)
The challenges posed by cancer heterogeneity (2012) (96)
Epigenetic Regulation of Cell Type–Specific Expression Patterns in the Human Mammary Epithelium (2011) (95)
A putative role for psoriasin in breast tumor progression. (2005) (94)
G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells (2017) (93)
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments (2019) (91)
Negative regulation of cell growth by TGFβ (1996) (90)
Cyclins, Cdks, and cyclin kinase inhibitors. (1994) (90)
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. (2016) (88)
p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. (2000) (88)
Sorting out the FACS: a devil in the details. (2014) (80)
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. (2013) (80)
Pregnancy and breast cancer: the other side of the coin. (2006) (80)
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (78)
On the birth of breast cancer. (2001) (78)
Somatic mutations in the notch, NF‐KB, PIK3CA, and hedgehog pathways in human breast cancers (2012) (77)
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. (2017) (76)
PTK6 Regulates IGF-1-Induced Anchorage-Independent Survival (2010) (75)
Erratum: Genetic determinants of p53-induced apoptosis and growth arrest ((Genes and Development (1996) 10 (1945-1952)) (1996) (74)
Stem cells in the human breast. (2010) (72)
HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. (2015) (70)
Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. (2009) (69)
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. (2020) (67)
Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors (2018) (66)
Tumor Heterogeneity Confounds and Illuminates: A case for Darwinian tumor evolution (2014) (66)
HIN-1, an Inhibitor of Cell Growth, Invasion, and AKT Activation (2005) (66)
Molecular markers for the diagnosis and management of ductal carcinoma in situ. (2010) (65)
Identification of CD44v6+/CD24− breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies (2009) (63)
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium (2011) (62)
Altered antisense-to-sense transcript ratios in breast cancer (2010) (61)
Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. (2015) (61)
CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. (2015) (61)
Cancer Cell Phenotypes, in Fifty Shades of Grey (2013) (60)
CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling. (1999) (58)
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations (2010) (56)
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. (2019) (56)
p27KIP1, an inhibitor of cyclin-dependent kinases. (1995) (53)
Epigenetic patterns of embryonic and adult stem cells (2009) (53)
Methylation‐specific digital karyotyping of HPV16E6E7‐expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis (2013) (53)
BET Bromodomain Proteins as Cancer Therapeutic Targets. (2016) (53)
Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer. (2015) (52)
Histone Demethylase Jumonji AT-rich Interactive Domain 1B (JARID1B) Controls Mammary Gland Development by Regulating Key Developmental and Lineage Specification Genes* (2014) (50)
Immune Escape during Breast Tumor Progression (2020) (50)
Serial Analysis of Gene Expression (SAGE) (2003) (50)
Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. (2004) (50)
SnapShot: breast cancer. (2012) (50)
BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells. (2016) (49)
Is Breast Tumor Progression Really Linear? (2008) (46)
Gene expression profiling of human breast tissue samples using SAGE-Seq. (2010) (46)
Detection of psoriasin/S100A7 in the sera of patients with psoriasis (2009) (45)
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. (2021) (45)
Targeting the missing links for cancer therapy (2011) (45)
S100A7-Downregulation Inhibits Epidermal Growth Factor-Induced Signaling in Breast Cancer Cells and Blocks Osteoclast Formation (2008) (44)
Myoepithelial cell‐specific expression of stefin A as a suppressor of early breast cancer invasion (2017) (43)
Age- and Pregnancy-Associated DNA Methylation Changes in Mammary Epithelial Cells (2015) (42)
Expression of high in normal-1 (HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissues (2002) (42)
The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women. (2016) (40)
Identifying key questions in the ecology and evolution of cancer (2021) (38)
Tracking tumor resistance using 'liquid biopsies' (2013) (37)
Cancer: Clonal cooperation (2014) (36)
Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer (2016) (36)
Metastasis as a systemic disease: molecular insights and clinical implications. (2019) (36)
Cyclooxygenase-2 expression during immortalization and breast cancer progression. (2008) (36)
EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis. (2019) (35)
Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer (2016) (34)
Breast Cancer Stem Cells: A Case of Mistaken Identity? (2007) (33)
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors. (2003) (33)
Negative regulation of cell growth by TGF beta. (1996) (33)
SAGE and related approaches for cancer target identification. (2006) (32)
TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer (2018) (32)
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ (2019) (31)
Dissecting the mammary gland one cell at a time (2018) (30)
Methylation-specific digital karyotyping (2006) (29)
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer (2020) (29)
Breast-cancer stromal cells with TP53 mutations. (2008) (28)
Molecular alterations in ductal carcinoma in situ of the breast (2002) (27)
Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9 (2008) (26)
On using functional genetics to understand breast cancer biology. (2012) (25)
Serial analysis of gene expression (2006) (23)
A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. (2012) (23)
Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS) (2018) (23)
Clonal evolution in cancer: a tale of twisted twines. (2015) (23)
Progress in breast cancer research (2012) (23)
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. (2019) (22)
The Expression of Psoriasin (S100A7) and CD24 Is Linked and Related to the Differentiation of Mammary Epithelial Cells (2012) (22)
MITI minimum information guidelines for highly multiplexed tissue images (2021) (22)
Breast tumor heterogeneity: causes and consequences (2009) (21)
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition (2020) (20)
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer (2021) (20)
Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling (2015) (18)
Less death in the dying (1997) (17)
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. (2020) (17)
Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System (2020) (14)
The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty? (2006) (14)
Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference (2017) (13)
Tumor Neoantigens: When Too Much of a Good Thing Is Bad. (2019) (13)
Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. (2011) (13)
Untangling the web of intratumour heterogeneity (2022) (13)
A roadmap for the next decade in cancer research (2020) (12)
Unraveling the complexity of basal-like breast cancer (2011) (12)
Serial Analysis of Gene Expression (SAGE) (2003) (12)
Cancer target discovery using SAGE (2003) (11)
Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress (2022) (11)
Breast cancer gene discovery (2002) (9)
EMSY links breast cancer gene 2 to the 'Royal Family' (2004) (8)
Phase II study of ruxolitinib , a selective JAK 1 / 2 inhibitor , in patients with metastatic triple-negative breast cancer (2018) (8)
Mathematical Modeling Links Pregnancy-Associated Changes and Breast Cancer Risk. (2017) (8)
Deletion of Cdkn1b in ACI rats leads to increased proliferation and pregnancy-associated changes in the mammary gland due to perturbed systemic endocrine environment (2019) (8)
Deconvoluting complex tissues for expression quantitative trait locus-based analyses (2013) (8)
Early-Life Body Adiposity and the Breast Tumor Transcriptome. (2020) (7)
Cyclooxygenase-2 expression during immortalization and breast cancer progression (Cancer Research (2008) 68, (467-475)) (2008) (7)
Abstract P4-06-01: JAK2/STAT3 activity in inflammatory breast cancer supports the investigation of JAK2 therapeutic targeting (2012) (6)
The mammary gland as an experimental model : a subject collection from Cold Spring Harbor perspectives in biology (2011) (6)
Tumor heterogeneity: the Lernaean hydra of oncology? (2014) (6)
Serial Analysis of Gene Expression (SAGE): Experimental Method and Data Analysis (2007) (6)
Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case–Control Analysis Nested within the Nurses' Health Study II (2020) (5)
Is p53 a Breast Cancer Gene? (2002) (5)
Going small is the new big (2010) (5)
Phase II study of ruxolitinib in patients with pStat3+ breast cancer. (2013) (5)
A confetti trail of tumour evolution (2018) (5)
Report of the First International Symposium on NUT Carcinoma. (2022) (4)
DCIS genomic signatures define biology and clinical outcome: Human Tumor Atlas Network (HTAN) analysis of TBCRC 038 and RAHBT cohorts (2021) (4)
Voices of biotech (2016) (4)
A Darwinian perspective on tumor immune evasion (2021) (4)
Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors (2018) (4)
HIN-1, an inhibitor of cell growth, invasion, and AKT1 activation (2005) (4)
The Expression of Psoriasin ( S 100 A 7 ) and CD 24 Is Linked and Related to the Differentiation of Mammary Epithelial Cells (2012) (3)
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. (2022) (3)
Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer (2018) (3)
Abstract P3-05-04: Intra-tumor heterogeneity as a predictor of therapy response in HER2 positive breast cancer (2012) (3)
The MCF10 Model of Breast Tumor Progression (2021) (3)
From cause to cure: Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics edited by A.M. Bowcock (1999) (2)
Abstract B16: Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer (2016) (2)
Breast cancer prevention by short-term inhibition of TGFβ signaling (2022) (2)
Advances in Brief A SAGE ( Serial Analysis of Gene Expression ) View of Breast Tumor Progression 1 (2001) (2)
Expression of estrogen receptor , progesterone receptor , and Ki 67 in normal breast tissue in relation to subsequent risk of breast cancer (2017) (2)
Gene expression profiling in breast cancer: from molecular portraits to personalized medicine (2004) (2)
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer (2022) (2)
Gene Expression: MRNA Transcript Analysis (2003) (2)
Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution. Commentary (2008) (2)
Gene Expression: Protein Analysis (2003) (1)
Abstract B62: Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in DCIS (ductal carcinoma in situ) (2018) (1)
Adaptation of the sequenom platform to the targeted determination of amplification and allele-specific imbalance in breast cancer (2008) (1)
A non-canonical EZH2 function sensitizes solid tumors to genotoxic stress (2020) (1)
On chromatin remodeling in mammary gland differentiation and breast tumorigenesis. (2012) (1)
Abstract P1-07-02: Mesenchymal stem cell regulated microRNAs converge on the speech gene FOXP2 and regulate breast cancer metastasis (2015) (1)
[Li-Fraumeni syndrome]. (2019) (1)
Abstract IA005: Immune escape during breast tumor progression (2021) (1)
Serial Analysis of Gene Expression (SAGE): Experimental Method and Data Analysis (2007) (1)
Complex interaction of yeast nuclear proteins with the enhancer/promoter region of SV40 (1991) (1)
JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States (2022) (1)
Overview: Gene Structure (2003) (1)
The role of the tumor microenvironment in breast cancer progression (2005) (1)
Expression of p 53 and p 21 proteins in various cell lines (2007) (0)
F-052SYNCHRONOUS MULTIPLE PRIMARY LUNG TUMOURS IN A GENETIC FAMILIAR SYNDROME: HOW TO APPROACH? (2017) (0)
Knockdown of Dermcidin (DCD) gene expression using RNAi vectors confirms its role as survival and growth factor to breast cancer cells (2007) (0)
Abstract A023: Sensitivity/resistance mechanisms to KDM5 inhibition in basal breast cancer (2022) (0)
Extracellular Matrix Biomarkers for Diagnosis, Prognosis, Imaging, and Targeting (2015) (0)
Abstract PD5-08: The human tumor atlas network (HTAN) breast pre cancer atlas: A multi-omic integrative analysis of ductal carcinoma in situ (DCIS) and correlation with clinical outcomes (2021) (0)
Breast cancer stem cells (2008) (0)
Advances in Brief Psoriasin Expression in Mammary Epithelial Cells in Vitro and in Vivo 1 (2001) (0)
DevelopmentMechanisms Guiding Embryonic Mammary Gland (2012) (0)
Dissecting the mammary gland one cell at a time (2018) (0)
Abstract PL05-01: Heterogeneity in DCIS and invasive breast cancers. (2013) (0)
Abstract S4-02: Principles governing A-to-I RNA editing in breast cancer transcriptome (2015) (0)
Classification Map Identifying Tumor Origin Using a Gene Expression-based Updated Version (2003) (0)
Functional relevance of histone demethylase JARID1B (KDM5B) in breast cancer (2015) (0)
Abstract ES1-1: Non-cell-autonomous drivers of tumor growth and progression (2017) (0)
Title: Evolutionary pathways in BRCA1-associated breast tumors (2012) (0)
Abstract P5-21-10: Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative breast cancer (2018) (0)
Breast Cancer Stem Cells: Reply (2007) (0)
A confetti trail of tumour evolution (2018) (0)
Abstract PR02: Minor clones can drive polyclonal metastasis by affecting immune microenvironment (2018) (0)
Pers Pe The Franz Abst Neo geneti numb betwe (2010) (0)
Breast tumor evolution. (2009) (0)
Abstract A020: Histone modification by Kmt2c and Kmt2d regulate metastasis in triple-negative breast cancer in vivo (2022) (0)
Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity. (2013) (0)
Abstract SY02-01: Regulators of in situ to invasive breast carcinoma progression. (2013) (0)
Global OMICs Profiling and Functional Analysis of CD44+/CD24− Stem-Like Cells in Normal Human Breast Tissue and Breast Cancer (2012) (0)
In situ to invasive carcinoma transition: escape or release (2003) (0)
Does the microenvironment regulate breast tumor progression (2006) (0)
Gene Analysis: DNA (2003) (0)
Abstract 4248: Methylation specific digital karyotyping of human papillomavirus type 16 E6E7 expressing keratinocytes identifies novel methylation targets in cervical carcinogenesis. (2013) (0)
In This Issue (2002) (0)
Tumor and Stem Cell Biology Targeting Akt 3 Signaling in Triple-Negative Breast Cancer (2014) (0)
Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling (2015) (0)
Gene D iscovery U sing t he S erial A nalysis o f G ene Expression T echnique: I mplications f or C ancer R esearch (2001) (0)
Cover Image (2003) (0)
Abstract ES8-3: Epigenetic heterogeneity in cancer (2015) (0)
S2-6: ErbB3 Expression Is Required for Maintenance of Normal and Transformed Luminal Breast Epithelial Cells. (2011) (0)
Abstract A21: Characterization of the immune environment in the in situ to invasive breast carcinoma transition (2018) (0)
Abstract SY17-01: Intratumor diversity in breast cancer (2012) (0)
Abstract IA1: Metastasis and diversity in breast cancer (2013) (0)
Is BreastTumor Progression Really Linear ? 55 Commentary on (2008) (0)
Abstract P6-14-09: Clinical outcomes of triple negative inflammatory breast cancer treated with contemporary anthracycline and taxane preoperative therapy support further investigation of therapeutic targets (2015) (0)
Molecular Biology, Genomics, and Proteomics (2003) (0)
Interview: Advancing translational research in breast cancer (2013) (0)
Erratum: Methylation-specific digital karyotyping (Nature Protocols (2006) vol. 1 (1621-1636) 10.1038/nprot.2006.278) (2006) (0)
Abstract BS1-2: Epigenetic targets in breast cancer (2017) (0)
Abstract GS4-07: The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts (2022) (0)
Tumor Progression and Serial Analysis of Gene Expression Analysis of Breast Combined cDNA Array Comparative Genomic Hybridization (2006) (0)
Abstract A15: Immune-related changes in breast cancer tumor evolution (2018) (0)
Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ (2016) (0)
Abstract PO-059: The genomic landscape of the in situ to invasive ductal breast carcinoma transition shaped by the immune system (2020) (0)
Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (0)
Abstract S5-05: Defective stalled replication fork repair and predisposition to hereditary breast cancer (2015) (0)
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (0)
Figure 1.5, [Constructing a genomic library. Genomic...]. (2000) (0)
Microenvironmental changes in breast tumor progression: genetic or epigenetic?. (2009) (0)
Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (0)
Title : CLK 2 is an oncogenic kinase and splicing regulator in breast cancer (2014) (0)
Abstract PL07-01: Molecular profiling of breast cancer in Mexico: Identification of novel therapeutic targets through whole genome sequencing analysis. (2012) (0)
Abstract PL03-03: The clinical significance of intratumor diversity in breast cancer (2011) (0)
Abstract B24: Targeting hyaluronan sensitizes breast cancer-associated fibroblasts to lapatinib and overcomes stromal resistance (2016) (0)
Abstract IA14: Breast tumor evolution: The role of the microenvironment (2018) (0)
Abstract IA11: Functional and clinical relevance of intratumor heterogeneity in breast cancer (2016) (0)
Abstract C283: Non-malignant cells from tissues targeted by metastatic breast cancer induce tumor cell resistance to antiestrogens and conventional chemotherapeutic agents. (2013) (0)
Abstract IA035: DCIS to IDC progression - a key step of immune escape (2022) (0)
Abstract P1-15-01: Withdrawn (2019) (0)
Characterization of IBC-1 A Novel Putative Breast Cancer Prognostic and Survival Factor (2004) (0)
The Hairy Powers of Oncogenes: From Biological Function to Cancer Therapy (2003) (0)
Abstract IA28: Epigenetic heterogeneity in breast cancer (2016) (0)
Bacterial Darth Vader: May the force be with you. (2022) (0)
The Human Tumor Atlas Network (HTAN) Breast PreCancer Atlas: A multi-omic integrative analysis of ductal carcinoma in situ with clinical outcomes (2021) (0)
Key signaling pathways in breast cancer based on somatic mutation data Frequency of breast cancer subtypes (2012) (0)
Parity and BRCA1/2-associated breast cancer risk linked to hormone-responsive p27 + luminal epithelial progenitors (2018) (0)
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer (2020) (0)
Identification of a Receptor for Tumor Suppressor HIN-1 (2003) (0)
Mitochondrial suitable as a tumor marker mutations that affect only one base pair (1999) (0)
Copy Number Variation in Inflammatory Breast Cancer (2023) (0)
Amplification and overexpresssion of IKBKE activates NF-kB pathway in breast cancers. (2007) (0)
Challenges and opportunities for modeling aging and cancer. (2023) (0)
Cellular and Molecular Targets of Estrogen in Normal Human Breast Tissue 1 (2002) (0)
ISOLATED p27 PROTEIN AND NUCLEIC ENSURE CODING (1995) (0)
SAGE-Seq Gene expression profiling of human breast tissue samples using Material (2010) (0)
Abstract IA26: Tumor evolution: From Darwin’s finches to breast cancer (2020) (0)
The Human Tumor Atlas Network (HTAN) Breast Precancer Atlas: A Multi-Omic Integrative Analysis of Ductal Carcinoma in situ With Clinical Outcomes (2021) (0)
Abstract A018: KDM4C histone demethylase connects redox balance to chromatin remodeling via histone H3 tail clipping (2022) (0)
Abstract SY38-02: Immune-related changes in breast tumor evolution (2016) (0)

This paper list is powered by the following services:

Other Resources About Kornelia Polyak

en.wikipedia.org

What Schools Are Affiliated With Kornelia Polyak?

Kornelia Polyak is affiliated with the following schools:

Kornelia Polyak's Academic­Influence.com Rankings

Kornelia Polyak's Degrees

Why Is Kornelia Polyak Influential?

Kornelia Polyak's Published Works

Published Works

Other Resources About Kornelia Polyak

What Schools Are Affiliated With Kornelia Polyak?

Kornelia Polyak's AcademicInfluence.com Rankings